focus -WSS

focus

author：focus 2025-10-06 16:00:31 Page View：34

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： STAT Summit: GSK CEO on pharma giant's new direction
Next article： Cancer drug shortages should be causing more outrage

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Will Ozempic

Wegovy,theobesitydrug,wasinescapableattheObesityWeekconferenceinDallas.ElaineChenDALLAS—HereatObesit

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

FDA gives detailed accounting of AI

AdobeTheFoodandDrugAdministrationonThursdayreleasedanewaccountingofartificialintelligencetoolscleare

focus

leisure time

knowledge

FDA gives detailed accounting of AI